Computational Biology Market size was over USD 7.91 Billion in 2023 and is projected to cross USD 83.76 Billion by the end of 2036, witnessing more than 19.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of computational biology is estimated at USD 9.33 Billion. The growth of the market can be attributed to the increasing use of computational approaches in the biological sciences to determine experimental data including genetic sequences, cell count, and protein sample detection for the discovery of new solutions in biology. The growing application of analytical methods, simulation technology, and mathematical modeling with computational models helps to discover new genomics and protein structures, propelling the market growth.
In addition to these, the rising need to prove many theoretical explanations in real-time applications is expected to drive the computational biology market growth. Increasing demand for bioinformatics, and growing clinical studies in the field of pharmacokinetics and pharmacogenomics with growing disease modeling. Further, escalating experiments to find the origin of the virus, host, and the virus evolution is driving the market demand.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
19.9% |
|
Base Year Market Size (2023) |
USD 7.91 Billion |
|
Forecast Year Market Size (2036) |
USD 83.76 Billion |
|
Regional Scope |
|
Application (Cellular & Biological Simulation, Drug Discovery, Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation)
The drug discovery segment is projected to garner a significant share of the computational biology market in the coming years, owing to the potential need for new medicines across the world. Drug discovery in general includes the involvement of complex processes such as pharmacological studies for the determination of drug efficacy, metabolic stability, bioavailability, and side effects in humans. These processes need permissions and funds from the government to perform which on the other hand drug discovery is done through computational technology on less budget.
The use of computational pharmacology helps to study the relation between genomic effects and diseases and the effects of drugs with the use of Microsoft Excel which propels the growth of the segment.
End-User (Academics, Industry, Commercials, Others)
The commercial segment is estimated to register a noteworthy computational biology market share during the forecast period with the increasing commercial investments by organizations in the research and development activities of the healthcare sector. Also, the growing privatization of the healthcare industry is estimated to boost the segment growth.
The increasing investment in genetic technology such as genetic engineering, genomics, automated cell culture, DNA sequencing, and cell biology is anticipated to hike the market demand. The net private equity and venture capital investment in the year 2021 increased at a rate of over 15% from 2010 for the life science category as per the estimations.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Component |
|
|
End User |
|
North American Market Forecast
North America region is anticipated to gain the largest computational biology market share till 2036, due to the growing R&D activities, coupled with the high investment in research activities.
The growing foothold of the United States in synthetic biology is predicted to promote lucrative opportunities for the market expansion. The advancement of the region in the application of machine learning tools and analytical tools will further influence the market growth.
APAC Market Statistics
Asia Pacific computational biology market is expected to witness substantial demand through 2036. The increasing presence of contract research organizations in the region that reduce the cost of drug development for many pharmaceutical industries will propel the market revenue.
The Asian market is popular for the manufacturing of generic drugs and biosimilars which is much essential to decrease healthcare expenditure and is set to drive the use of computational biology in the region.
Certara Inc. announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded the company’s licenses of Certra’s proprietarybiosimulation software along with other 400 user licenses of Phoenix software and Simcyp.
Instem Group declared the acquisition of Edge Software Consultancy Ltd to expand its portfolio to discover R&D activities thereby bringing the client products into the market at a faster rate. The technology and services of the Edge helped to enhance the research and development activities of drug discovery and increased client productivity.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?